1. Home
  2. SEVN vs IPHA Comparison

SEVN vs IPHA Comparison

Compare SEVN & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Seven Hills Realty Trust

SEVN

Seven Hills Realty Trust

HOLD

Current Price

$7.65

Market Cap

184.4M

Sector

Real Estate

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$1.79

Market Cap

165.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SEVN
IPHA
Founded
1986
1999
Country
United States
France
Employees
N/A
163
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
184.4M
165.3M
IPO Year
2008
N/A

Fundamental Metrics

Financial Performance
Metric
SEVN
IPHA
Price
$7.65
$1.79
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
4
Target Price
$10.50
$5.75
AVG Volume (30 Days)
159.5K
5.3K
Earning Date
04-28-2026
03-26-2026
Dividend Yield
13.90%
N/A
EPS Growth
N/A
N/A
EPS
0.19
N/A
Revenue
$29,383,000.00
N/A
Revenue This Year
$27.75
$180.36
Revenue Next Year
$4.06
N/A
P/E Ratio
$40.11
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.37
$1.18
52 Week High
$11.15
$2.62

Technical Indicators

Market Signals
Indicator
SEVN
IPHA
Relative Strength Index (RSI) N/A 45.08
Support Level N/A $1.60
Resistance Level N/A $1.78
Average True Range (ATR) 0.00 0.06
MACD 0.00 -0.01
Stochastic Oscillator 0.00 17.29

Price Performance

Historical Comparison
SEVN
IPHA

About SEVN Seven Hills Realty Trust

Seven Hills Realty Trust is a real estate investment trust. The company is engaged in originating and investing in floating-rate first mortgage loans secured by middle-market and transitional commercial real estate. Its primary objective is to balance capital preservation with the generation of risk-adjusted returns. The company operates in one business segment: originating and investing in floating-rate first mortgage loans secured by CRE properties.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: